DelveInsight, a leading business consulting and market research company, has released its latest report, “Obesity Market Insight, Epidemiology, and Market Forecast – 2036,” providing comprehensive insights into obesity epidemiology, treatment practices, marketed and emerging therapies, and market dynamics across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the Obesity Market Report
The obesity market in the 7MM is projected to grow substantially by 2036 due to expanding use of incretin-based therapies and increasing treatment uptake.
DelveInsight estimates that the obesity market size in the 7MM was approximately USD 16 billion in 2025 and is anticipated to increase significantly through 2036.
According to DelveInsight’s analysis, the United States represented approximately 60% of the total prevalent obesity cases across the 7MM in 2025.
In the US, around 5.5 million children aged 5–19 years were living with obesity in 2025.
Germany reported approximately 18 million prevalent obesity cases in 2025, representing the highest disease burden among EU4 and the UK.
Existing marketed therapies include WEGOVY, ZEPBOUND, SAXENDA, CONTRAVE/MYSIMBA, and QYSMIA.
WEGOVY and ZEPBOUND continue to dominate the obesity treatment landscape owing to their strong efficacy profiles and expanding global approvals.
In April 2026, Eli Lilly announced that the US FDA approved FOUNDAYO (orforglipron) for adults with obesity or overweight and weight-related comorbidities.
Emerging therapies including Retatrutide, Survodutide, CagriSema, VK2735, Amycretin, MariTide, CT-388, and Pemvidutide are expected to reshape future obesity management.
The obesity pipeline is highly competitive, with several therapies in Phase III clinical development demonstrating promising efficacy and metabolic benefits.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market
Key Factors Driving the Obesity Market
Increasing Global Obesity Burden
Rising prevalence of obesity among adults and children continues to fuel demand for effective long-term treatment strategies. Sedentary lifestyles, dietary changes, and metabolic disorders are contributing significantly to disease growth worldwide.
Growing Adoption of GLP-1 and Dual/Triple Agonist Therapies
The success of GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Therapies targeting GLP-1, GIP, and glucagon receptors are delivering unprecedented weight reduction outcomes compared to older therapies.
Expanding Awareness of Obesity as a Chronic Disease
Healthcare systems and medical societies increasingly recognize obesity as a chronic metabolic disease associated with major comorbidities including cardiovascular disease, diabetes, hypertension, and sleep apnea, driving greater treatment adoption.
Advancements in Precision and Combination Therapies
Emerging personalized approaches and multi-target metabolic therapies are improving efficacy, metabolic control, and long-term treatment outcomes while expanding therapeutic options for patients.
Obesity Competitive Landscape
The obesity market is currently dominated by incretin-based therapies such as WEGOVY (semaglutide) and ZEPBOUND (tirzepatide), which have demonstrated substantial weight loss efficacy and growing physician adoption globally.
Key Marketed Therapies
WEGOVY (semaglutide) – Novo Nordisk
ZEPBOUND (tirzepatide) – Eli Lilly
SAXENDA (liraglutide) – Novo Nordisk
CONTRAVE/MYSIMBA (naltrexone-bupropion)
QYSMIA (phentermine-topiramate)
Emerging Therapies in Development
Survodutide (BI 456906) – Boehringer Ingelheim
Retatrutide – Eli Lilly
CagriSema – Novo Nordisk
VK2735 – Viking Therapeutics
Amycretin – Novo Nordisk
Pemvidutide (ALT-801) – Altimmune
MariTide – Amgen
CT-388 – Carmot Therapeutics/Roche
FOUNDAYO (orforglipron) – Eli Lilly
RGT-075 – Regor Therapeutics
These emerging therapies are expected to intensify competition and expand treatment accessibility over the forecast period.
Discover more about therapies set to grab major Obesity Market share @ Obesity Market Landscape
Recent Developments in the Obesity Market
In April 2026, Eli Lilly announced US FDA approval of FOUNDAYO (orforglipron) for obesity and overweight patients with weight-related comorbidities.
In January 2026, Novo Nordisk announced broad US availability of oral WEGOVY, the first oral GLP-1 therapy approved for weight loss.
In December 2025, Novo Nordisk submitted an NDA to the US FDA for CagriSema for chronic weight management.
In September 2025, Regeneron reported positive interim Phase II COURAGE trial data evaluating semaglutide combinations for obesity treatment.
Orforglipron demonstrated significant weight loss and cardiometabolic benefits in the ATTAIN-1 study published in The New England Journal of Medicine.
What is Obesity?
Obesity is a chronic, multifactorial, non-communicable disease characterized by excessive adiposity or body fat accumulation that adversely impacts health. It results primarily from an imbalance between energy intake and energy expenditure, influenced by environmental, psychosocial, metabolic, and genetic factors.
Diagnosis is generally based on Body Mass Index (BMI), calculated as weight in kilograms divided by height squared in meters. Obesity is associated with increased risks of cardiovascular disease, diabetes, hypertension, sleep apnea, metabolic syndrome, and several other chronic disorders.
Obesity Epidemiology Segmentation
The obesity epidemiology section in the report provides historical and forecasted data across the 7MM from 2022–2036, segmented into:
Total Prevalent Cases of Obesity
Adult Obesity Cases
Childhood Obesity Cases
Total Treated Cases of Obesity
Country-specific Obesity Burden
Patients Seeking Treatment
Therapy-specific Treated Population
Scope of the Obesity Market Report
Comprehensive overview of obesity pathophysiology and treatment landscape
Historical and forecasted obesity market size analysis
Epidemiology segmentation across the 7MM
Assessment of marketed and emerging therapies
Competitive landscape and pipeline analysis
Market drivers, barriers, SWOT, and unmet needs
KOL perspectives and analyst insights
Market access and reimbursement analysis
To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment
Table of Contents
Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Obesity Market Overview at a Glance
Disease Background and Overview
Diagnosis
Treatment and Management
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Emerging Therapies
Obesity Market Analysis
KOL Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading business consulting and market research company focused exclusively on life sciences. The company provides comprehensive market intelligence, epidemiology forecasting, pipeline analysis, and strategic consulting services to pharmaceutical and biotechnology companies worldwide.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: https://www.delveinsight.com/consulting/due-diligence-servicesCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
